Screening looks for disease before symptoms appear. It is not the same checklist for everyone: age, personal and family history, previous results, medications and personal preferences determine which tests are truly useful.
In regions where it is offered, HPV testing is recommended every 5 years for women and people with a cervix aged 25 to 65 who have no symptoms and are at average risk.
For immunocompromised people, the usual interval is 3 years. During the transition from a normal Pap test, the first HPV test is generally done 3 years later.
A positive HPV result does not mean cancer; it means additional analysis or follow-up is needed. Unusual vaginal bleeding, especially after intercourse, requires diagnostic assessment rather than waiting for screening.
For an average-risk person aged 50 to 74 with no symptoms or relevant history, the fecal immunochemical test is recommended every 2 years.
The sample is collected at home. A positive result does not confirm cancer, but it usually leads to colonoscopy.
Rectal bleeding, black stool, a persistent change in bowel habits, anemia, weight loss, or significant personal or family history may require a different and faster pathway.
The Québec Breast Cancer Screening Program invites insured women aged 50 to 74 to have a mammogram every 2 years.
Before age 50, after 74, or with high risk — such as a genetic mutation, previous chest radiation or a strong family history — the decision and interval are individualized.
A new lump, bloody nipple discharge, recent nipple retraction or skin change should be assessed without waiting for the next screening mammogram.
A lipid panel is often offered around age 40, or earlier with smoking, high blood pressure, diabetes, kidney disease, obesity or a family history of premature cardiovascular disease.
Results include total, LDL and HDL cholesterol and triglycerides, but treatment decisions depend mainly on overall cardiovascular risk rather than one isolated number.
For an untreated person at low risk, yearly testing is usually unnecessary; a 5- to 10-year interval may be reasonable if no new risk factor appears. Follow-up differs when treatment or cardiovascular disease is present.
Diabetes Canada recommends fasting glucose and/or hemoglobin A1C every 3 years beginning at age 40, or earlier for people at high risk.
Risk factors include family history, prediabetes or gestational diabetes, excess weight, hypertension, sleep apnea and membership in some higher-risk ethnic populations.
Testing every 6 to 12 months may be appropriate at very high risk. Without symptoms, an abnormal result usually needs confirmation with a second test.
Québec does not have a universal organized prostate screening program. PSA testing is a shared decision after discussing possible earlier detection and the harms of false positives, biopsies, overdiagnosis and unnecessary treatment.
For men who choose screening and have a life expectancy greater than 10 years, Canadian recommendations generally suggest starting at age 50, or 45 for increased risk such as family history or Black ancestry.
Between ages 50 and 70, the interval depends on the previous PSA and overall risk. An elevated PSA should usually be repeated and interpreted in clinical context before deciding about biopsy.
Screening generally stops around age 70 or earlier when life expectancy is under 10 years, but the decision remains individualized.
DXA bone-density testing is suggested for postmenopausal women and men at age 70 even without risk factors; from age 65 with at least one risk factor; and from age 50 to 64 after an osteoporosis-related fracture or with at least two risk factors.
Important risks include a fragility fracture after age 40, parental hip fracture, long-term corticosteroid use, smoking, low body weight, repeated falls and certain secondary medical conditions.
DXA results are combined with a tool such as FRAX to estimate 10-year fracture risk. A fragility fracture, height loss or new spinal pain requires assessment without waiting for routine screening.
These intervals mainly apply to asymptomatic adults at average risk. Personal or family history, previous surgery, pregnancy, immunosuppression and earlier abnormal results often change the schedule.
An abnormal screening test is not always a diagnosis and needs a defined follow-up. A normal result also cannot guarantee that disease will never develop.
At your preventive visit, bring the dates and results of previous tests. Your family physician can build a practical plan that avoids both missed screening and unnecessary testing.
At Bina Clinic, prevention is based on individual risk and shared decision-making. The best screening schedule is one that fits your medical history and includes a clear plan for following every result.
This article provides general information and does not replace a personalized medical assessment, diagnosis or treatment.
Follow-up care for individuals and families—chronic condition monitoring, pediatrics, results review, and prescription renewals when appropriate. In-person visits with telemedicine available for select concerns when clinically appropriate.
Answers to the questions our guests ask most — from booking to your visit, explained with care.
